Publications

 

The NH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.

ASH 2021

Oral Presentations:

Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant CyclophosphamideScott R. Solomon, MD1, Michael T Aubrey2*, Xu Zhang, PhD3*, Katelin C Jackson1*, Christina L Roark2*, Brian M Freed2*, Lawrence E Morris, MD1, H. Kent Holland, MD1, Asad Bashey, MD, PhD1 and Melhem Solh, MD1

Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive MismatchesScott R. Solomon, MD1, Michael T Aubrey2*, Xu Zhang, PhD3*, Melhem Solh, MD1, Lawrence E Morris, MD1, H. Kent Holland, MD1, Katelin C Jackson1*, Brian M Freed2*, Christina L Roark2* and Asad Bashey, MD, PhD1

Collaborative Oral Presenations:

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study– Manali Kamdar, MD1, Scott R. Solomon, MD2, Jon E. Arnason, MD3, Patrick B. Johnston, M.D., Ph.D.4, Bertram Glass, MD5*, Veronika Bachanova, MD, PhD6, Sami Ibrahimi, MD7, Stephan Mielke, MD8, Pim G.N.J. Mutsaers, MD, PhD9*, Francisco J. Hernandez-Ilizaliturri, MD10, Koji Izutsu, MD, PhD11*, Franck Morschhauser, MD, PhD12,13*, Matthew A. Lunning, DO, FACP14, David G. Maloney, MD, PhD15, Alessandro Crotta, MD16*, Sandrine Montheard, MS17*, Alessandro Previtali, MSc16*, Lara Stepan, BS18*, Ken Ogasawara, PhD, MPH19*, Timothy Mack, PhD18* and Jeremy S. Abramson, MD.

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies– Bijal D. Shah, MD1, Caron Jacobson, MD2, Scott R. Solomon, MD3,4, Nitin Jain, MD5, Mark C. Johnson, PhD6*, Monika Vainorius, MD6*, Lou Yu, PhD7*, Christopher R. Heery, MD6, Alan F. List, MD6, Fiona He, MD8,9, Ran Reshef, MD, MSc10, Luke P. Akard, MD11, Craig S. Sauter, MD12, Adam J. Olszewski, MD13, Abhinav Deol14 and Koen van Besien, MD, PhD.

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic ‘Off-the-Shelf’ CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL– Nitin Jain, MD1, Hagop Kantarjian, MD1, Scott R. Solomon, MD2, Fiona He, MD3, Craig S. Sauter, MD4, Christopher R. Heery, MD5, Alan F. List, MD5, Mark C. Johnson, PhD5*, Yu Lou, MSc5*, Monika Vainorius, MD5*, Koen van Besien, MD, PhD6, Adam J. Olszewski, MD7, Anthony S. Stein, MD8 and Bijal D. Shah, MD.

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3- Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1-Michael Sebag, MD, PhD1, Noopur S. Raje, MD2, Nizar J. Bahlis, MD3, Caitlin Costello, MD4, Bhagirathbhai Dholaria, MBBS5, Melhem Solh, MD6, Moshe Y. Levy, MD7,8, Michael H. Tomasson, MD9, Harman Dube, PhD10*, Michael A. Damore, PhD10*, Hoi Ken Lon, PhD10*, Cynthia Basu, PhD11*, Athanasia Skoura, PhD12*, Edward Chan, MD13*, Suzanne Trudel, MD14, Andrzej Jakubowiak15, Michael P. Chu, MD16, Cristina Gasparetto, MD17, Andrew P. Dalovisio, MD18 and Alexander Lesokhin, MD19

Poster Presentations:

Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor UseAsad Bashey, MD, PhD1, Xu Zhang, PhD2*, H. Kent Holland, MD1, Lawrence E Morris Jr., MD1*, Scott R. Solomon, MD1 and Melhem Solh, MD1

High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II TrialScott R. Solomon, MD1, Melhem Solh, MD1, Stacey Brown, CCRP1*, Nancy Shegda1*, Katelin C Jackson1*, Xu Zhang, PhD2*, Lawrence E Morris, MD1, Asad Bashey, MD, PhD1 and H. Kent Holland, MD11Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,2Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

Impact of Choice of Induction Regimen on Overall Survival and Post-Remission Survival Among Older Adults with Acute Myeloid Leukemia– Kelli McCrum, PharmD1*, Justin LaPorte, PharmD2*, Asad Bashey, MD, PhD3, Scott R. Solomon, MD3, Lawrence E Morris, MD3, H. Kent Holland, MD3 and Melhem Solh, MD3,

The Intensity of the Induction Regimen Does Not Affect Post-Transplant Survival Among Patients with Newly Diagnosed Mantle Cell LymphomaMelhem Solh, MD1, Asad Bashey, MD, PhD1, Lawrence E Morris, MD1, H. Kent Holland, MD1, Xu Zhang, PhD2* and Scott R. Solomon, MD11Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,2 Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse, Melhem Solh, MD1, Asad Bashey, MD, PhD1, Scott R. Solomon, MD1, Lawrence E Morris, MD1, Xu Zhang, PhD2* and H. Kent Holland, MD11Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA,2Center for Clinical and Transitional Sciences, University of Texas Health Science Center, Houston, TX

Collaborative Poster Presentations:

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML-Tomasz Rzymski, PhD1*, Urszula Pakulska, PhD1*, Camille Abboud Sr., MD2, Howard A. Burris Sr., MD3, Scott R. Solomon, MD4, Marta Obacz1*, Kristina Goller1*, Michal Combik, PhD1*, Jan Zaucha, MD, PhD5*, Milena Mazan, PhD1*, Michal Mikula, PhD6*, Magdalena Cybulska6*, Anna Polak7*, Przemyslaw Juszczynski, MD, PhD8*, Marcus Järås, PhD9, Marion Chapellier, PhD9*, Johan Flygare, MD, PhD10, Magdalena Zawadzka, PhD1*, Karolina Bukowska Strakova, PhD11*, Krzysztof Brzozka, PhD1*, Setareh Shamsili, MD, PhD1* and Noemi Angelosanto, MD.

The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine Achieved responses in Patients with Diffuse Large B-Cell Lymphoma Who Relapsed after Anti-CD19 CAR T-Cell Therapy– Paolo F. Caimi, MD1, Kirit M. Ardeshna, MD, MA, FRCP, FRCPath2, Erin Reid, MD, MS3, Weiyun Z. Ai, MD, PhD4, Matthew A. Lunning, DO, FACP5, Jasmine Zain, MD6, Melhem Solh, MD7, Brad S. Kahl, MD8 and Mehdi Hamadani, MD.

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma– Krish Patel, MD1, Jean-Marie Michot, MD2*, Asher Chanan-Khan, MBBS, MD3, Herve Ghesquieres, MD, PhD4*, Kamal Bouabdallah, MD5*, John C. Byrd, MD6, Guillaume Cartron, MD, PhD7*, Craig A. Portell, MD8, Melhem Solh, MD9, Hervé Tilly, MD10, William G. Wierda11, Patricia McGovern, MS12*, Chelsea Johnson, BSN, RN13*, Raman Garcha, MD12*, Vincent Ribrag, MD14, Gabriel Brisou, MD15*, David Liebowitz, MD12 and Tycel Phillips, MD.

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)– Jeremy S. Abramson, MD1, M. Lia Palomba, MD2, Leo I. Gordon, MD3, Matthew A. Lunning, DO, FACP4, Michael Wang, MD5, Jon E. Arnason, MD6, Enkhtsetseg Purev, MD, PhD7*, David G. Maloney, MD, PhD8, Charalambos Andreadis, MD, MS9, Alison R. Sehgal, MD10, Scott R. Solomon, MD11, Nilanjan Ghosh, MD, PhD12, Ana Kostic, MD13*, Yeonhee Kim, PhD13*, Ken Ogasawara, PhD, MPH14*, Christine Dehner, BSc13* and Tanya Siddiqi, MD.

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation– Camille Abboud Sr., MD1,2, Gautam Borthakur, MD3, Scott R. Solomon, MD4, Howard A. Burris Sr., MD5, Terrence Bradley, MD6, JAN Maciej Zaucha Sr.7*, Ewa Lech-Marańda, MD, PhD8*, Krzysztof Brzozka, PhD9*, Tomasz Rzymski, PhD9*, Peter Littlewood, BSc10*, Elie Mouhayar, MD11*, Setareh Shamsili, MD, PhD9* and Noemi Angelosanto, MD.

Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome– Alice S. Mims, MD1, Melhem Solh, MD2, Jennifer N. Saultz, DO3, Uma Borate, MD4, Naveen Pemmaraju, MD5, Gautam Borthakur, MD5, Gail J. Roboz, MD6, Ben Powell, PhD7*, Bernice Matusow7*, Jason Halladay, PhD7*, Shireen Vali, PhD7*, Chelsea L. Hope, PhD7*, Madan G. Kundu, PhD8*, Ching Hsu, PhD8*, Paul Watkins7*, Chao Zhang, PhD7*, Jackie M. Walling, PhD, MD7, Athanasios C. Tsiatis, MD7 and Amy E. DeZern, MD.

Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial– Juan Pablo Alderuccio, MD1, Weiyun Z. Ai, MD, PhD2, John Radford3*, Melhem Solh, MD4, Kirit M. Ardeshna, MD, MA, FRCP, FRCPath5, Matthew A. Lunning, DO, FACP6, Brian T. Hess, MD7, Pier Luigi Zinzani, MD, PhD8, Anastasios Stathis, MD9*, Carmelo Carlo-Stella, MD10, Mehdi Hamadani, MD11, Brad S. Kahl, MD12, David Ungar13, Turk Kilavuz14*, Eric Yu15*, Yajuan Qin15* and Paolo F. Caimi, MD.

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study– Jeremy S. Abramson, MD1, Scott R. Solomon, MD2, Jon E. Arnason, MD3, Patrick B. Johnston, M.D., Ph.D.4, Bertram Glass, MD5*, Alessandro Crotta, MD6*, Sandrine Montheard, MS7*, Alessandro Previtali, MSc6*, Fei Fei Liu, BSc, MBA8*, Julia Braverman, PhD8*, Shien Guo, PhD9*, Ling Shi, PhD9* and Manali Kamdar, MD.

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101– Claudio G. Brunstein, MD, PhD1, Paul V O’Donnell, MD2*, Brent R. Logan, PhD3*, Luciano J. Costa, MD, PhD4, Corey Cutler, MD, MPH, FRCPC5, Michael Craig, MD6, William J Hogan, MB, BCh7, Mary M. Horowitz, MD, MS3, Mitchell E. Horwitz, MD8, Chatchada Karanes, MD9, John M. Magenau, MD10*, Adriana Malone, MD11*, John M McCarty, MD12*, Joseph P. McGuirk, DO13, Lawrence E Morris, MD14, Andrew R. Rezvani, MD15, Witold Rybka16*, Rachel Beth Salit, MD17*, Sumithira Vasu, MBBS18, Mary Eapen, MBBS, MS19 and Ephraim J. Fuchs, MD, MBA.1

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial- Alessandro Paoli1*, Daniela Bellarosa, PhD1*, Alessandro Bressan1*, Francesco Bertolini, MD, PhD2, Scott R. Solomon, MD3, Pau Montesinos, PhD, MD4*, Sudipto Mukherjee, MD, PhD, MPH5, Stephen A Strickland6, Giovanni Marconi, MD7*, Armando Santoro8*, Roland B. Walter, MD9, Rachel J. Cook, MD10, Maria Calbacho, MD11*, Susana Vives12*, Salman Fazal, MD13*, Farhad Ravandi, MBBS14, Krzysztof Brzozka, PhD15*, Tomasz Rzymski, PhD15*, Milena Mazan15*, Simone Baldini, MD1*, Niccolò Ravenni1*, Monica Binaschi, PhD1*, Dirk Laurent, MD1* and Andrea Pellacani, PhD,

 

ASH 2020 Collaborative Oral Presentations:

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings, Jacqueline S. Garcia, MD1, Yael Flamand, MS2*, Benjamin K. Tomlinson, MD3, Michael Keng, MD4*, Lourdes M. Mendez, MD, PhD5, Samer Khaled, MD6, Asad Bashey, MD, PhD7, Andrew M. Brunner, MD8, Alexandra Savell, BS1*, Donna Neuberg9*, Ilene Galinsky10*, Marlise R. Luskin, MD11, David P. Steensma, MD1, Martha Wadleigh, MD10*, Eric S. Winer, MD10, David E. Avigan, MD12, Nicole Cullen11*, Scott Rodig, MD, PhD13,14, Livius Penter1*, R. Coleman Lindsley, MD, PhD1, Stephanie Andrews11*, Matthew S. Davids, MD1, Catherine J. Wu, MD1, Richard M. Stone, MD10, Daniel J. DeAngelo, MD, PhD15 and Robert J. Soiffer, MD16

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study, Farhad Ravandi, MBBS1, Asad Bashey, MD, PhD2, Wendy Stock, MD3, James M. Foran, MD4, Raya Mawad, MD5*, Daniel Egan, MD6*, William Blum, MD7*, Allen Yang, MD, PhD8, Alessandro Pastore, MD9, Chelsea Johnson, BSN, RN8*, Shuo Zheng8*, Musa Yilmaz, MD10 and Alice S. Mims, MD11

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens, Mahasweta Gooptu, MD1, Andrew St. Martin, MS2*, Rizwan Romee, MD3, Mukta Arora, MD4, Monzr M. Al Malki, MD5, Joseph H. Antin, MD3, Christopher Bredeson, MD, FRCPC, MSc6, Claudio G. Brunstein, MD, PhD4, Saurabh Chhabra, MD7, Ephraim J. Fuchs, MD, MBA8, Nilanjan Ghosh, MD, PhD9, Michael R. Grunwald, MD9, Yoshihiro Inamoto, MD10, Christopher G. Kanakry, MD11*, Natasha Kekre, MD, MPH, FRCPC6, Joseph P. McGuirk, DO12, Ian K. McNiece, PhD13*, Rohtesh S. Mehta, MD, MPH, MS14, Marco Last Mielcarek, MD15*, Filipo Milano, MD, PhD16, Dipenkumar Modi, MD17, Ran Reshef, MD18, Mark A. Schroeder, MD19, Robert J. Soiffer, MD3, Scott R. Solomon, MD20, Edmund K. Waller, PhD, MD21 and Mary Eapen, MBBS, MS22

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001, Maria Lia Palomba, MD1, Leo I. Gordon, MD2, Tanya Siddiqi, MD3*, Jeremy S. Abramson, MD4*, Manali Kamdar, MD5*, Matthew A. Lunning, DO, FACP6, David G. Maloney, MD, PhD7, Charalambos Andreadis, MD, MSCE8*, Jon E. Arnason, MD9, Nilanjan Ghosh, MD, PhD10, Amitkumar Mehta, MD11, Scott R. Solomon, MD12, Thalia Farazi, MD, PhD13*, Jacob Garcia, MD13*, Christine Dehner, BSc13*, Ken Ogasawara, PhD, MPH14*, Jie Gao, PhD14* and Michael Wang, MD15

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), William G. Wierda, MD, PhD1, Kathleen A. Dorritie, MD2, Javier Munoz, MD3, Deborah M. Stephens, DO4, Scott R. Solomon, MD5, Heidi H. Gillenwater, MD6*, Lucy Gong, PharmD6*, Lin Yang, PhD6*, Ken Ogasawara, PhD, MPH7*, Jerill Thorpe, BS6* and Tanya Siddiqi, MD8*

Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders,  Jeffrey E. Lancet, MD1, Geoffrey L Uy, MD2, Laura F. Newell, MD3, Tara Lin, MD4, Donna E. Hogge5*, Scott R. Solomon, MD6, Gary J. Schiller, MD7, Matthew J. Wieduwilt, MD, PhD8, Daniel H. Ryan9, Stefan Faderl10, Yu-Lin Chang10* and Jorge E. Cortes, MD11,12

ASH 2020 Poster Presentations:

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical TransplantationAsad Bashey, MD, PhD1, Xu Zhang, PhD2*, Lawrence E Morris, MD1, H. Kent Holland, MD1, Scott R. Solomon, MD3 and Melhem Solh, MD1

ASH 2020 Collaborative Poster Presentations:

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience, Siddharth Jayant Kunte, MD1, Lisa Rybicki, MS2*, Auro Viswabandya, MD3, Asad Bashey, MD, PhD4, Madiha Iqbal, MBBS5, Michael R. Grunwald, MD6, Bhagirathbhai Dholaria, MBBS7, Hany Elmariah, MD, MS8, Michael Ozga, MD9, Anurag K. Singh, MD10, Sameem Abedin, MD11, Vikas Gupta, MD, FRCP, FRCPath12, Amy E. DeZern, MD13, Richard J. Jones, MD13, Aaron T. Gerds, MD, MS14 and Tania Jain, MD15

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), Alexander M. Lesokhin, MD1, Moshe Y. Levy, MD2, Andrew P. Dalovisio, MD3, Nizar Bahlis, MD4, Melhem Solh, MD5, Michael Sebag, MD, PhD, FRCPC6, Andrzej Jakubowiak, MD, PhD7, Yogesh S. Jethava, MBBS, MD, FRCPath, MRCP8, Caitlin L. Costello, MD9, Michael P. Chu, MD10, Michael R. Savona, MD11, Cristina Gasparetto, MD12, Suzanne Trudel, MD, MSC, FRCPC13, Jeffrey Chou, MD, PhD14*, Chandrasekhar Udata, PhD15*, Cynthia Basu, PhD15*, Heike I. Krupka, PhD, PMP14* and Noopur S. Raje, MD16

Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Paolo F Caimi1*, Weiyun Z. Ai2, Juan Pablo Alderuccio, MD3, Kirit M. Ardeshna4, Mehdi Hamadani, MD5, Brian T. Hess, MD6, Brad S. Kahl, MD7, John A. Radford, MD, FMedSci8*, Melhem Solh, MD9, Anastasios Stathis, MD10*, Pier Luigi Zinzani, MD11, Jay Feingold12*, David Ungar13, Yajuan Qin13*, Shui He13* and Carmelo Carlo-Stella, MD14

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome, Alice S. Mims, MD1, Melhem Solh, MD2, Uma Borate3, Naveen Pemmaraju, MD4, Gautam Borthakur, MD5, Gail J. Roboz, MD6, Ben Powell, PhD7*, Paul Severson, PhD7*, Bernice Matusow7*, Jason Halladay, PhD7*, Ching Hsu, PhD8*, Paul Watkins7*, Chao Zhang, PhD7*, Jackie M. Walling, PhD, MD7, Athanasios C. Tsiatis, MD7 and Amy E. DeZern, MD9

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching, Ephraim J. Fuchs, MD, MBA1, Shannon R McCurdy, MD2*, Scott R. Solomon, MD3, Tao Wang, PhD4*, Michelle Kuxhausen, MS5*, Yvette L Kasamon, MD1*, MHD Monzr Al Malki, MD6, Shahinaz Gadalla, MD, PhD7*, Sophie Paczesny, MD, PhD8, Steven GE Marsh, BSc, PhD, ARCS9*, Bronwen E. Shaw, PhD, MRCP, FRCPath10, Stephen R. Spellman, MS11*, Stephanie J. Lee, MD, MPH11,12 and Effie Petersdorf, MD13*

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial, Andrea Massimiliano Tomirotti, PhD1*, Daniela Bellarosa2*, Scott R. Solomon, MD3, Aziz Nazha, MD4, Stephen A Strickland, MD, MSCI5, Roland P Walter, MD PhD6, Farhad Ravandi, MBBS7, Krzysztof Brzózka, PhD8, Milena Mazan, PhD9*, Simone Baldini, MD10*, Massimiliano Salerno11*, Monica Binaschi, PhD12*, Dirk Laurent, MD13* and Andrea Pellacani, PhD, MD14*

2020 Translation and Cellular Therapy Tandem Meeting:

Extracorporeal Photopheresis (ECP) Improves Overall Survival in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease (SR aGVHD), ABSTRACT #17687

 

ASH 2019 Poster Presentations:

Improved Survival of Patients diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls– ABSTRACT# 123230

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation- ABSTRACT# 123545

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide- ABSTRACT# 124354

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T-Replete Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide- ABSTRACT#  131624

A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies- ABSTRACT# 131608

A Psychological and Social Factors are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score- ABSTRACT# 131639

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidenical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy- ABSTRACT# 131661

ASH 2018

Oral Presentations:

Solomon S, Aubrey M, Anobile C, Zhang X, Freed B, Morris LE, Holland HK, Solh M, Bashey A.  Class II epitope level mismatch can predict chronic graft-versus-host disease and survival following haploidentical transplant using post-transplant cyclophosphamide. ORAL ABSTRACT #311                       

Solomon S, Martin A, Shah N, Fatobene G, Al Malki, M, Ballen K, Bashey A, Bejanyan N, Bolanos-Meade J, Brunstein C, Defilipp Z, Champlin R, Fuchs E, Hamadani M, Hematti P, Kanakry C, McGuirk J, McNiece I, Ciurea S, Pasquini M, Rocha V, Romee R, Patel S, Vasu S, Waller E, Wingard J, Zhang M, Eapen M.  T-replete haploidentical cell transplantation using post-transplant cyclophosphamide for acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome:  Effect of transplant conditioning regimen intensity of outcomes.  ORAL ABSTRACT #1015

Solh M, Solomon S, Morris LE, Holland HK, Zhang X, Bashey A.  The choice of induction regimen affects post remission survival of acute myelogenous leukemia (AML) patients with intermediate or poor risk disease.  ORAL ABSTRACT #82                       

Collaborative Oral Presentation:

Caimi P, Kahl B, Hamadani M, Carlo-Stella C, Ardeshna KM, Radford J, Solh M, Heffner L, He, S, Ungar D, Qin Y, O’Connor OA.  Safety and efficacy of ADCT-402 (loncastuximab tesirine) a novel antibody drug conjugate in relapsed/refractory follicular lymphoma and mantle cell lymphoma: Interim results from the phase I first in human study. ORAL ABSTRACT #626

Poster Presentations:

Solomon S, Jackson K, Zhang X, Solh, M, Bashey A, Holland HK, Morris LE.  Treatment patterns and outcomes of unselected elderly acute myeloid leukemia (AML) patients referred to a combined acute leukemia and hematopoietic stem cell transplant (HSCT) program. POSTER ABSTRACT #2675

Solomon S, Zhang X, Solh M, Morris LE, Holland HK, Bashey A.  Long-term follow-up of myeloablative haploidentical (HID) peripheral blood stem cell transplantation and post-transplant cyclophosphamide (PTCy) following fludarabine and total body irradiation (TBI). POSTER ABSTRACT # 3368

Ravandi-Kashani F, Abboud C, Akard L, Gill S, Hsu J, Kambhampati S, Khan I, Delong L, Stock W, Brown J, Bashey A, Borthakur G, Dinardo C, Holland HK, Kadia T, Kantarjian H, Morris LE, Solomon S, Mamelok R, Panuganti S, Syoc R, Wong A, Zimmerman D, Solh M. Evaluation of ASH 2018 romyelocel-L myeloid progenitors cells to decrease infections in de novo AML patients receiving high-dose ara c-based induction therapy. POSTER ABSTRACT #1407 

ASBMT Tandem Meeting 2018

Oral Presentation:
Solh M, Zhang X, Brown S, Morris LE, Holland HK, Bashey A, Solomon S. The dilemma of conditioning intensity:  When does myeloablative conditioning improve outcomes for allogeneic hematopoietic cell transplantation?  ORAL ABSTRACT # 68

Post Presentations:
Sizemore C, Ridgeway M, Zhang X, Morris LE, Holland HK, Solh M, Bashey A, Solomon S.  Rituximab based on first line treatment for chronic GVHD following allogeneic transplant:  Single center analysis of 95 patients.  POSTER ABSTRACT # 224 

Kronemberg O, Miller J, Sizemore C, Hanik M, Brown S, Bashey A, Solomon S, Morris LE, Holland HK, Solh M.  A prospective pilot study of implementing a sepsis management protocol among adult hematopoietic stem cell transplant recipients.  POST ABSTRACT # 564.

ASH 2017

Oral Presentation:
Solomon S, Aubrey M, Zhang X, Piluso A, Freed B, Brown S, Jackson K, Solh M, Morris LE, Holland HK, Bashey A.  Selecting the best donor for T cell-replete haploidentical transplantation:  Importance of HLA disparity, NK alloreactivity, and other clinical variables.  ORAL ABSTRACT #670 

Collaborative Oral Presentation:

Kahl B, Hamadani M, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardeshna K, Radford J, Solh M, Hung K-Y, Heffner L, He S, Boni J, O’connor O.  Early results from the first in human clinical trial of ADCT-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine based antibody drug conjugate, in relapsed/refractory B-cell lineage non-hodgkin lymphoma ORAL ABSTRACT #670 

Poster Presentations:
Bashey A, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Solh M, Solomon S.  Comparison of outcomes following allogeneic HCT for adverse cytogenetic/molecular risk AMl using T-replete haploidentical donors to optimally matched related and unrelated donors. POSTER ABSTRACT #4608

Solh M, Bashey A, Zhang X, Morris LE, Holland KH, Solomon S.  Myeloablative hematopoietic cell transplantation (HCT) for low and intermediate disease risk index myeloid malignancies results in better outcomes compared to reduced intensity HCT. POSTER ABSTRACT #2050

Baron J, Ridgeway M, Zhang X, Bashey A, Solomon S, Holland HK, Morris LE, Solh M.  Identifying risk factors for acute and chronic graft versus host disease in T-replete HLA-haploidentical hematopoietic cell transplantation with post transplant cyclophosphamide. POSTER ABSTRACT #1977

Solh M, Zhang X, Solomon S, Morris LE, Holland HK, Bashey A.  Who is a better donor for recipients of allogeneic hematopoietic cell transplantation:  A young HLA haploidentical relative or an older fully matched HLA-matched sibling or unrelated volunteer? POSTER  ABSTRACT #4604 

Collaborative Poster Presentation:

Goldberg, A, Tallman M, Solh M, Ungar D, Rizzieri D, Walter R, Spira A, Chung K-Y, Stock W, He S, Boni J, Atallah E.  Interim data from a phase 1 study evaluating pyrrolobenzodiazapine-based antibody drug conjugate ADCT-301 (Camidanlumab Tesirine) for relapsed or refractory CD25-positive acute leukemia. POSTER ABSTRACT #302

ASBMT Tandem Meeting 2017

Oral Presentations:

Sanacore M, Eaton S, Morris LE, Solomon S, Bashey A, Solh M, Holland HK.  Prospective assessment of diagnostic infectious disease molecular PCR testing with early fiber-optic bronchoscopy (FOB) in the evaluation of new pulmonary infiltrates in hematopoietic stem cell transplantation (HSCT) and acute leukemia (AL) patients (pts). ORAL ABSTRACT # 9355

Solh M, Dickhaus E, Gruber L, Bashey A, Solomon S, Holland HK, Morris LE, Brown S.  Fevers post infusion of T-cell replete HLA mismatched haploidentical hematopoietic stem cells.  ORAL ABSTRACT
 # 8901

Poster Presentations:

Solh M, Gorgeis J, Sizemore C, Solomon S, Holland HK, Morris LE, Bashey A.  Nitazoxanide is effective therapy for norovirus gastroenteritis after hematopoietic stem cell transplantation.  POSTER ABSTRACT # 348

Solomon S, Aubrey, Zhang X, Freed B, Piluso A, Connor K, Brown S, Holland HK, Morris LE, Solh M, Bashey A.  Impact of donor characteristics on transplant outcome following haploidentical hematopoietic cell transplantation utilizing post-transplant cyclophosphamide:  Improving donor selection criteria.  POSTER ABSTRACT # 309

LaPorte J, Leon K, Zhang X, Morris LE, Solomon S, Holland HK, Solh M, Bashey A.  A unique schedule of Palanosetron, Ondansetron and Dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. POSTER ABSTRACT # 230

ASH 2016

Oral Presentations:

Solomon S, Sizemore C, Ridgeway M, Zhang X, Solh M, Morris LE, Holland HK, Bashey A. Current graft-versus-host-disease (GVHD), relapse-free Survival – a novel, dynamic composite endpoint to better define effectiveness following allogeneic hematopoietic cell transplantation.  ORAL ABSTRACT #1170

Bashey A, Zhang X, Brown S, Jackson K, Solh M, Lawrence M, Holland HK, Solomon S.Myeloablative allogeneic hematopoietic cell transplantation performed without routine inpatient admission:  A single center experience of 462 consecutive patients. ORAL ABSTRACT #661

Bashey A, Zhang M, Mccurdy S, Ciurea S, St. Martin A, Anasetti C, Argall T, Fasan O, Gaballa S, Hamandani M, Malki M, Munshi P, Nakamura R, O’Donnell P, Perales M, Raj K, Rocha V, Romee R, Rowley S, Salit R, Solh M, Soiffer R, Wingard J, Weisdorf D, Horowitz M, Fuchs E, Eapen M. Comparison of peripheral blood stem cells (PBSC) to bone marrow (BM) for T-replete HLA-Haploidentical donor transplantation using post-transplant cyclophosphamide. ORAL ABSTRACT #683

Poster Presentations:
Solh M, Bashey A, Solomon S, Morris LE, Zhang X, Brown S, Holland HK. Excellent long term survival among patients who are disease-free at one year after allogeneic hematopoietic cell transplantation:  A single center analysis of 667 consecutive patients.  POSTER ABSTRACT #4622

Solh M, Bashey Z, Solomon S, Morris LE, Holland HK, Zhang X. Outcomes for allogeneic hematopoietic cell transplantation for AML and high grade MDS in older adults in the era of T-replete haploidentical donor grafts.  A single center multivariate analysis. POSTER ABSTRACT #4665

Solh M, Morris LE, Holland HK, Solomon S, Brown S, Bashey A. Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation (HCT):  A single center analysis of 613 adult HCT recipients using a modified composite endpoint. POSTER ABSTRACT #4574

ASH 2015

Oral Presentation:

Bashey A, Zhang X, Jackson K, Brown S, Solh M, Morris LE, Holland HK, Solomon S. Non-Inferior survival of black versus white patients and superior outcomes for black females compared to other race/gender groups following allogeneic transplantation for hematologic malignancy:  A single center multivariable analysis of 475 allografted patients.  ORAL ABSTRACT #401

Poster Presentations:

Bashey A, Zhang X, Jackson K, Brown S, Solh M, Morris LE, Holland HK, Solomon S. Lineage specific chimerism analysis reveals that mixed donor T-cell chimerism is common in the early post-transplant period following myeloablative allotransplants from HLA-matched but not HLA-haploidentical donors:  A multivariable analysis of allografted patients from a single center.  POSTER ABSTRACT #4327

Solomon S, Sizemore C, Zhang X, Solh M, Morris LE, Holland HK,  Bashey A. Disease risk index is the major predictor of outcome following myeloablative haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and post-transplant cyclophosphamide (PT/Cy).   POSTER ABSTRACT #2010

Solomon S, Sizemore C, Zhang X, Connor K, Solh M, Holland HK, Morris LE, Bashey A.  Disease risk and host factors, not transplant type, predict outcome following allogeneic hematopoietic stem cell transplantation for acute leukemia.  POSTER ABSTRACT #4372

Solomon S, Sanacore M, Zhang X, Connor K, Solh M, Bashey A, Morris LE, Holland HK.  Targeted oral busulfan (BU/cyclophosphamide (CY)/VP-16 and autologous stem cell transplant (ASCT) for Hodgkins’s (HL) and non-hodgkin’s lymphoma (NHL) results in excellent 5-year survival and low treatment related mortality:  Ten-year single center experience of 246 consecutively treated patients.   POSTER ABSTRACT #3185

Solomon S, Sanacore M, Zhang X, Connor K, Solh M, Morris LE, Holland HK, Bashey A.  In vivo T cell depletion with thymogobulin of alemtuzumab is associated with worse outcome following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients transplanted in remission.    POSTER ABSTRACT #3115

Solh M, Zhang X, Brown S, Morris LE, Holland HK, Solomon S, Bashey A.  Lower use of DLI post relapse of malignancy may result in shorter post-relapse survival (PRS) in patients undergoing T cell replete haploidentical donor transplantation (HIDT) versus matched related (MRD) or matched unrelated donor (MUD) hematopoietic cell transplantation (HCT). POSTER ABSTRACT #1967

Solh M, Connor K, Zhang X, Brown S, Morris LE, Holland HK, Bashey A. Solomon S. T cell replete HLA- haploidentical donor transplantation (HIDT) with post-transplant cylophosphamide (pTcy) is an effective salvage for patients relapsing after a matched sibling or a matched unrelated donor transplantation.   POSTER ABSTRACT #1960

Solh M, Zhang X, Connor K, Brown S, Holland HK, Morris LE, Solomon S, Bashey A.  Factors predicting GVHD free, relapse free survival (GRFS) after allogeneic hematopoietic cell transplantation; a multivariable analysis of 531 allografts from a single center.  POSTER ABSTRACT #2028

Collaborative 2015 ASH Abstracts:

Bart L Scott, MD, Marcelo C. Pasquini, MD, Brent Logan, PhD, Juan Wu, Steve Devine, MD*, David L Porter, MD, Richard T. Maziarz, MD, Erica Warlick, MD, Hugo F. Fernandez, M.D., Edwin P. Alyea, MD, Mehdi Hamadani, MD, Asad Bashey, MD, PhD, Sergio A. Giralt, MD, Eric Leifer, PhD, Nancy Geller, PhD, Jennifer Le-Rademacher, PhD, Adam M. Mendizabal, PhD, Mary M. Horowitz, MD, MS, H. Joachim Deeg, MD1 and Mitchell E. Horwitz, MD, Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN), ABSTRACT #0901

Matthew S. Davids, MD, Haesook T. Kim, PhD, Caitlin L. Costello, MD, Peter A. McSweeney, MD, Rebecca Liguori, Alexander Lukez, David Avigan, MD, Yi-Bin Chen, MD, Nicole LeBoeuf*, Vincent T. Ho, MD, Corey S Cutler, MD, MPH, John Koreth, MBBS, DPhil, Edwin P. Alyea, MD5, Joseph H Antin, MD5, Jerome Ritz, MD, Philippe Armand, MD, PhD, Edward D Ball, MD, Asad Bashey, MD, PhD and Robert J. Soiffer, MD, A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation,  ABSTRACT #860

Anand Jillella, MD1, Martha Arellano, MD, Asad Bashey, MD, PhD, Sarah I. Vidito, DO, Robert K. Stuart, MD, Caleb Leung*, Kaitlin Sitchenko, Manila Gaddh, MD, Leonard T Heffner Jr., MD, Ravindra B. Kolhe, MD, PhD*, Jacques Galipeau, MD, Amelia Langston, MD and Vamsi K Kota, MD, Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA, ABSTRACT #3779

Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD, PhD, Judith E Karp, MD and B. Douglas Smith, MD, Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia, Jonathan Allen Webster, MD, Raoul Tibes, MD, PhD, Amanda Blackford, ScM, ,  ABSTRACT # 2563

ASH 2014

Oral Presentations:

Scott R. Solomon, M.D., H. Kent Holland, M.D., Lawrence E. Morris, M.D., Asad Bashey, M.D., Ph.D., Connie Sizemore, PharmD, Xu Zhang, Ph.D., Stacey Brown, B.A., Katelin Connor, B.S. TBI-Based Myeloablative Haploidentical Stem Cell Transplantation is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors –ORAL ABSTRACT #426

Kent Holland, M.D., Scott R. Solomon, M.D., Lawrence E. Morris, M.D. Asad Bashey, M.D., Ph.D, Xu Zhang, Ph.D. ,. Dawn Speckhart, Ph.D. The Psychosocial Transplant Evaluation Rating Scale (TERS) Prospectively Predicts Inferior Overall Survival Outcome for High Risk Scoring Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. ORAL ABSTRACT #207

Stefan O. Ciurea, M.D., Mei-Jie Zhang, M.D., Andrea Bacigalupo, M.D., Asad Bashey, M.D., Ph.D. Survival after T-Replete Haplo-identical Related Donor Transplants Using Post-Transplant Cyclophosphamide Compared with Match Unrelated Donor Transplantation for Acute Myeloid Leukemia:  An Analysis from the CIBMTR.  ORAL ABSTRACT #679

Poster Presentations:Scott R. Solomon, M.D., Lawrence E. Morris, M.D., H. Kent Holland, M.D., Asad Bashey, M.D., Ph.D.  Michelle Ridgeway, RN, OCN, Xu Zhang, Ph.D., Stacey Brown, B.A. Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation.  Connie Sizemore, PharmD, POSTER ABSTRACT #2487

Ron Mihelic, PharmD, BCOP, H. Kent Holland, M.D., Scott R. Solomon, M.D., Lawrence E. Morris, M.D., Asad Bashey, M.D., Ph. D., Xu Zhang, Ph.D., Elizabeth Dickhaus, PharmD, Stacey Brown, B.A. Flag-Idarubicin Is Superior to Cytarabine Plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML):  A Multivariable Analysis of Patients Treated at a Single Center.  POSTER ABSTRACT #3728

Asad Bashey, M.D., Ph.D., H. Kent Holland, M.D., Lawrence E. Morris, Scott R. Solomon, M.D., Xu Zhang, Ph.D, Stacey Brown, B.A., Katelin Connor, B.S.Use of the Dana-Farber/CIBMTR Disease Risk Index (DRI) to Compare Outcomes of T-Replete HLA-Haploidentical Transplants Using Post-Transplant Cyclophosphamide to Matched Sibling and Matched Unrelated Donor Transplants:  A Multivariate Analysis of 498 contemporaneous Allogeneic Transplants from a Single Center.  POSTER ABSTRACT #1203

Asad Bashey, M.D., Ph.D., H. Kent Holland, M.D., Lawrence E. Morris, M.D., Scott R. Solomon, M.D., Xu Zhang, Ph.D., Stacey Brown, B.A., Katelin Connor, B.S.Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplantation Using Post-Transplant Cyclophosphamide:  A Multivariate Analysis of 116 Consecutive Transplants from a Single Center.  POSTER ABSTRACT #3922

Kent Holland, M.D., Lawrence E. Morris, M.D., Scott Solomon, M.D., Asad Bashey, M.D., Ph.D., Xu Zang, Ph.D., Stacey Brown, B.A. Impact of Age on Outcomes Following Autologous Stem Cell Transplantation for Multiple Myeloma. Justin LaPorte, PharmD, POSTER ABSTRACT #3968

ASBMT Tandem Meeting: 2014 Poster Presentation:

Laporte,J, Mihelic R , Sanacore M, Sizemore C, Leech M, Holland HK, Morris LE, Solomon S, Bashey A. Outcomes of Relapse of AML Post Allogeneic Transplantation in the Era of Hypomethylating Agents: An Analysis of 162 Allogeneic Transplants from a Single Center.

Mihelic, R, Sanacore M, Sizemore C, Leech M, Laporte, Holland HK,  Morris LE, Solomon S, Bashey A.  FLAG-Idarubicin is Superior to Cytarabine plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML): A Multivariable Analysis of Patients Treated at a Single Center.

ASH 2013

Oral Presentation:

Melissa Sanacore, PharmD, Asad Bashey, MD, PhD, Connie A. Sizemore, PharmD, H. Kent Holland, MD, Lawrence E. Morris, MD, Stacey Brown, B.A., Xu Zhang, PhD and Scott R. Solomon, MD. Calcineurin Inhibitor-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT).

Poster Presentations:

Asad Bashey, MD, PhD, Xu Zhang, PhD, Zaamin Hussain, Stacey Brown, B.A., Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD. Overall and Disease-Specific Outcomes Following T-Cell Replete Haploidentical Transplants Using Post-Transplant Cyclophosphamide: An Analysis Of 115 Patients Transplanted At a Single Center.

Scott R. Solomon, MD, Stephanie Jacobson, FNP-C, OCN, Melissa Sanacore, PharmD, Xu Zhang.  Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Single Center .

Mindy Leech, Moshe Stewart, Xu Zhang, Asad Bashey, Kent Holland, Scott Solomon, Hetty Caraway, B Douglas Smith, Lawrence Morris, Steven D. Gore, and Amer M. Zeidan. Validation of a brief arsenic trioxide (ATO)-based consolidation chemotherapy in the upfront management of acute promyelocytic leukemia (APL): less anthracycline exposure and faster completion of consolidation therapy with equivalent survival.

Justin LaPorte, Xu Zhang, Zaamin Hussain, Stacey L. Brown, Connie Sizemore, Melissa Sanacore, Ron Mihelic, Mindy Leech, Lawrence E. Morris Jr,MD,  H. Kent Holland, MD, Scott R. Solomon, MD, and Asad Bashey, MD. Implementation of a Systematic Approach to Increase Occurrence and Documentation of Fertility Discussions in Newly Diagnosed Acute Leukemia Patients Prior to Induction Chemotherapy. Outcomes of Relapse of AML Post Allogeneic Transplantation in the Era of Hypomethylating Agents: An analysis of 162 Allogeneic Transplants from a Single Center

ASBMT Tandem Meeting: 2013 Poster Presentation:

Sizemore C, Zang X, Sanacore M, Bashey A, Solomon S, Morris LE, Holland HK.  Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome.

 

2013 11th Annual American Psychosocial Oncology Association Meeting

Oral Presentation:

Dawn Speckhart, Ph.D. University of Colorado, Denver and the Colorado Blood Cancer Institute, Presbyterian/St.Luke’s Medical Center.  Disease Comorbidity Predicts Length of Hospitalization Whereas Psychosocial Risk Predicts Patient Survival One Year Post Hematopoietic Stem Cell Transplantation’, ABSTRACT #0250.

Dawn Speckhart, Ph.D., Implementation of a Systematic Approach to Increase Occurrence and Documentation of Fertility Discussions in Newly Diagnosed Acute Leukemia Patients Prior to Induction Chemotherapy’.

ASH 2012

Poster Presentation(s):

Sizemore C, Zang X, Sanacore M, Bashey A, Solomon S, Morris LE, Holland HK.  Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome.   Poster at NCI’s International Workshop on the Biology, Prevention and Treatment of relapse after Hematopoietic Stem Cell Transplantation.

Hussain A, Sizemore C, Zhang X, Sanacore M, Brown S, Manion K, Morris LE, Holland HK, Solomon S, Bashey A.  Lineage-Specific Chimerism and Incidence of Graft Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eight-Nine Consecutive Patients From a Single Center

Speckhart D, Solomon S, Holland HK, Morris LE, Bashey AB.  Assessing Fatigue and Distress in Caregivers of Hematopoetic Stem Cell Transplant Patients

ASBMT Tandem Meeting – 2012
Oral Presentation:

Sanacore M, Sizemore C, Zhang X, Schipani B, Morris LE, Bashey A, Holland HK, Solomon S. Effect of Cytoxan dosing on hematopoietic stem cell (HSC) mobilization efficacy, toxicity and cost in successive cohorts of non-hodgkin’s  lymphoma (NHL) patients.

Poster Presentations:

Leech M, Laporte J, Mihelic R, Sanacore M, Sizemore C, Holland HK, Morris LE, Solomon S, Bashey A.  Pharmacy driven posaconazole therapeutic monitoring in leukemia and bone marrow transplant center

Leech M, Laporte J, Mihelic R, Sanacore M, Sizemore C, Holland HK, Morris LE, Bashey A, Solomon S. Voriconazole therapeutic monitoring in a leukemia and bone marrow transplant center.

Laporte J.  Leech M, Mihelic R, Sanacore M, Sizemore C, Zhang X, Holland HK,  Morris LE, Bashey A, Solomon S. An effective hematopoietic stem cell mobilization algorithm for adding plerixafor to G-CSF for multiple myeloma patients undergoing autologous transplantation

—–Back To Top—–

ASH 2011

Oral Presentations:

Haploidentical transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival:  Results of a prospective phase II trial. Sizemore C, Bashey A, Sanacore M, Manion K, Holland HK, Morris LE, Brown S,Zhang X, Solomon S.

T-Cell replete haploidentical transplantation using post-transplant cyclophosphamide results in equivalent non-relapse mortality and disease-free survival compared to transplantation from HLA-identical sibling and matched unrelated donors:  A stratified cox model analysis of two hundred and sixty   contemporaneous allogeneic transplants from a single center.  Bashey A, Zhang X, Sizemore C, Manion K, Brown S, Holland HK, Solomon S, Morris LE.

Low dose subcutaneous alemtuzumab and preemptive donor lymphocyte infusion without withdrawal of immunosuppression results in low non-relapse mortality, decreased hospitalization, and favorable outcomes for high risk older recipients of unrelated donor allogeneic transplants:  A prospective
phase II trial. Sizemore C, Bashey A, Manion K, Holland HK, Morris LE, Brown S, Zhang X,
Solomon S.

—–Back To Top—–

Publications:  Highlights

Brunstein CG, O’Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, Horowitz MM, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ; Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012, Blood and Marrow Transplant Clinical Trials Network, Transplant Cell Therapy, 2022 Jul;28(7):406.e1-406.e6.

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS, Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial, Lancet, 2022 Jun 18;399(10343):2294-2308.

Solomon SR, Aubrey MT, Zhang X, Jackson KC, Roark CL, Freed BM, Morris LE, HollandHK, Solh MM, Bashey A., Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand, Transplant Cell Therapy, 2022 Jul 1:S2666-6367(22)01432-4

Alderuccio JP, Ai WZ, Radford J, Solh MM, Ardeshna KM, Lunning M, Hess B, Luigi Zinzani P, Stathis A, Carlo Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin YG, Caimi PF., Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study, Blood Advances, 2022 Jul 5:bloodadvances.2022007782.

Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M., The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy, Clinical Lymphoma Myeloma Leukemia, 2022 May;22(5):e335-e339.

Solomon SR, Brown S, Shegda N, Jackson KC, Zhang X, Bashey A, Holland HK, Morris LE, Solh M., High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma, Transplant Cellular Therapy, 2022 May 20:S2666-6367(22)01313-6.

D’Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE., Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma, American Journal of Hematology, 2022 May 14. doi: 10.1002/ajh.26596.

Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D.,
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.

Bone Marrow Transplant, 2022 May;57(5):852.

Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R., The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis, Haematologica, 2022 Apr 21.

Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M.,
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
, Blood, 2021 Jul 22;138(3):273-282.

Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon YT, Saad A, McGuirk J, Paczesny S, Gadalla SM, Marsh SGE, Shaw BE, Spellman SR, Lee SJ, Petersdorf EW, HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide, Blood, 2022 Mar 10;139(10):1452-1468.

Guru Murthy GS, Kim S, Hu ZH, Estrada-Merly N, Abid MB, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Diaz Perez MA, Farhadfar N, Gale RP, Ganguly S, Gergis U, Hildebrandt GC, Grunwald MR, Hashmi S, Hossain NM, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Hamilton BK, Lazarus HM, Liesveld J, Litzow M, Marks DI, Murthy HS, Nathan S, Nazha A, Nishihori T, Patel SS, Pawarode A, Rizzieri D, Savani B, Seo S, Solh M, Ustun C, van der Poel M, Verdonck LF, Vij R, Wirk B, Oran B, Nakamura R, Scott B, Saber W., Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors, JAMA Oncology, 2022 Mar 1;8(3):404-411.

Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, Iqbal M, Grunwald MR, Dholaria B, Elmariah H, Ozga M, Singh A, Abedin S, DeZern AE, Jones RJ, Gupta V, Gerds AT, Jain T.,Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study, Leukemia, 2022 Mar;36(3):856-864.

Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D’Souza A., Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation, Transplant Cell Therapy, 2022 Feb;28(2):83.e1-83.e9. doi: 10.1016/j.jtct.2021.10.022.

O’Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, Horowitz MM, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani AR, McGuirk JP, Jones RJ, Eapen M., Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes,Transplant Cellular Therapy, Transplant Cell Ther. 2022 Feb;28(2):109.e1-109.e8.

Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O’Donnell L, O’Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies, Journel of Clinical Oncology, 2022 Feb 1;40(4):356-368.

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W,
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
, Blood Advances, 2022 Jan 11;6(1):339-357.

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W., Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia, Blood  Advances,2022 Jan 11;6(1):339-357.

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W.,  Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML, Blood Advances. 2022 Jan 8;6(3):828-847.

Orfali N, Zhang MJ, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Diaz MA, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, van Besien K, Eapen M., Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy,Transplant Cell Therapy, 2021 Dec;27(12):993.e1-993.e8.

Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D., An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis, Bone Marrow Transplant, 2021 Dec;56(12):3068-3077.

Hess B, Townsend W, Ai W, Stathis A, Solh M, Alderuccio JP, Ungar D, Liao S, Liao L, Khouri L, Zhang X, Boni J., Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma, AAPS J. 2021 Dec 10;24(1):11.

Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM., Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation, British Journel of Haematology. 2021 Dec;195(5):757-763.

Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, Horowitz MM, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O’Donnell L, O’Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA., Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies, J Clin Oncol. 2021 Dec 2:JCO2102293.

Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH., Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS), Cancer. 2021 Dec 1;127(23):4421-4431.

Oran B, Ahn KW, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, Weisdorf D, Marks DI, Rizzieri D, Copelan E, Hildebrandt GC, Hale GA, Murthy HS, Lazarus HM, Cerny J, Liesveld JL, Yared JA, Yves-Cahn J, Szer J, Verdonck LF, Aljurf M, van der Poel M, Litzow M, Kalaycio M, Grunwald MR, Diaz MA, Sabloff M, Kharfan-Dabaja MA, Majhail NS, Farhadfar N, Reshef R, Olsson RF, Gale RP, Nakamura R, Seo S, Chhabra S, Hashmi S, Farhan S, Ganguly S, Nathan S, Nishihori T, Jain T, Agrawal V, Bacher U, Popat U, Saber W., Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes,Transplant Cell Ther. 2021 Nov; 27(11):921.e1-921.e10

Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F., Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia, Journal of Clinical Oncology. 2021 Oct 10;39(29):3261-3272.

Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher U, Badawy SM, Bejanyan N, Bhatt VR, Bredeson CN, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla SM, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus HM, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson RF, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan CS, Sandmaier BM, Litzow MR, Kebriaei P, Weisdorf DJ, Zhang Y, Tallman MS, Saber W., Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML, Blood Advances. 2021 Sep 22:bloodadvances.2021004881.

Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM., Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, 2021 Sep;56(9):2319.

—–Back To Top—–

Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, Ahmed EH, Schlotter S, Pearson R, Kitzler R, Mozhenkova A, Le-Rademacher J, Little RF, Akpek G, Ayala E, Devine SM, Kaplan LD,

Noy A, Popat UR, Hsu JW, Morris LE, Mendizabal AM, Krishnan A, Wachsman W, Williams N, Sharma N, Hofmeister CC, Forman SJ, Navarro WH, Alvarnas JC, Ambinder RF, Lozanski G, Baiocchi RA., Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial, Front Immunology. 2021 Sep 3;12:700045.

Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C.,
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
, Leukemia, 2021 Sep;35(9):2672-2683.

Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood, 2021 Jul 22;138(3):273-282.

Mulroney CM, Abid MB, Bashey A, Chemaly RF, Ciurea SO, Chen M, Dandoy CE, Diaz Perez MA, Friend BD, Fuchs E, Ganguly S, Goldsmith SR, Kanakry CG, Kim S, Komanduri KV, Krem MM, Lazarus HM, Ljungman P, Maziarz R, Nishihori T, Patel SS, Perales MA, Romee R, Singh AK, Reid Wingard J, Yared J, Riches M, Taplitz R., Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation, Br J Haematol. 2021 Jul;194(1):145-157.

Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Cortes JE., CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial, Lancet Haematol, 2021 Jul;8(7):e481-e491.

Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-

Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A., Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era., Leukemia. 2021 Jul;35(7):2141.

Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS., Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant, JAMA Oncology, 2021 Jul 1;7(7):993-1003.

Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME.
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial
, Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6.

Desai P, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Open-Label Phase II prospective randomized controlled study of Romyelocel-L myeloid progenitor cells to reduce infection during induction chemotherapy for Acute Myeloid leukemia, Journal of Clinical Oncology, 2021 jun 22

Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C., Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial, Lancet Oncology, 2021 Jun;22(6):790-800.

Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea S, Dandoy CE, Díaz MÁ, Fuchs E, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri KV, Krem MM, Lazarus HM, Liu H, Ljungman P, Masiarz R, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz R, Romee R, Riches M., Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis, Blood, 2021 Jun 10;137(23):3291-3305.

Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S,

Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A., Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era., Leukemia. 2021 Jun;35(6):1828. doi: 10.1038/s41375-021-01233-1.

Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O’Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS.,
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
, Blood, 2021 May 13;137(19):2634-2645

Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS., Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 May 6. doi: 10.1001/jamaoncol.2021.1074. Epub ahead of print. PMID: 33956047.

Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M., Blood Cancer Journal, 2021 Apr 29;11(4):82.

Ferrari V, Tarke A, Fields H, Ferrari L, Conley T, Ferrari F, Koşaloğlu-Yalçın Z, Sette A, Peters B, McCarthy CL, Bashey A, Tzachanis D, Ball ED, Tanaka TN, Bejar R, Lane TA, Vitiello A., In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden, Cytotherapy, 2021 Apr; 23(4):320-328.

Jillella AP, Arellano ML, GadJidh M, Langston AA, Heffner LT, Winton EF, McLemore ML, Zhang C, Caprara CR, Simon KS, Bolds SL, DeBragga S, Karkhanis P, Krishnamurthy SH, Tongol J, El Geneidy MM, Pati A, Gerber JM, Grunwald MR, Cortes J, Bashey A, Stuart RK, Kota VK., Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia, JCO Oncol Pract, 2021 Apr;17(4):e497-e505.

Ercival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM., Impact of depth of clinical response on outcomes of acute myeloid

leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Apr 16. doi: 10.1038/s41409-021-01261-6. Epub ahead of print. Erratum in: Bone Marrow Transplant. 2021 May 20;: PMID: 33864019.

Gooptu M, Romee R, St Martin A, Arora M, Al Malki MM, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece I, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M. HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood, 2021 Apr 13.

Giza SA, Sethi S, Smith LM, Empey MET, Morris LE, McKenzie CA.J, The application of in utero magnetic resonance imaging in the study of the metabolic and cardiovascular consequences of the developmental origins of health and disease, Dev Orig Health Dis., 2021, Apr:12(2): 193-202.

Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan- Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D’Souza A., Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era, Leukemia, 2021 Mar 29.

Solh MM, Hinojosa G, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A., A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T- Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies. Adv Hematol, 2021 Mar 23;2021:8868142.

Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv., 2021 Mar 23;5(6):1719-1728.

Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C., Allogeneic transplantation after PD-1 blockade for classic classic Hodgkin lymphoma, Leukemia, 2021 Mar 3.

Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea SO, Dandoy CE, Angel Diaz M, Fuchs EJ, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri K, Krem M, Lazarus HM, Liu H, Ljungman P, Maziarz RT, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz RA, Romee R, Riches M., Post-Transplant Cyclophosphamide (PTCy) is Associated with increased Cytomegalovirus Infection: A CIBMTR Analysis, Blood, 2021 Mar 3.

Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D’Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M., Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation, Transplant Transplant Cell Therapy 2021, Feb 26. S2666-6367(21)00717-X.

Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME, Myeloablative versus Reduced-Intensity Conditioning for  Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic-Syndromes Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial, Transplant Cell Therapy, 2021 Feb 26. S2666-6367(21)00718-1.

Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M., Alternative donor transplantation for  myelodysplastic syndromes: haploidentical relative and matched unrelated donors, Blood Adv., 2021 Feb 23;5(4):975-983.

—–Back To Top—–

Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O’ Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR., Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis, Bone Marrow Transplant 2021 Feb;56(2):522.

Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier BM, Litzow M, Kebriaei P, Saber W, Weisdorf D., Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study, Transplant Cell Ther. 2021 Jan;27(1):68.e1-68.e9.

Fuchs EJ, O’Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, Horowitz MM, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG., Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial, Blood. 2021 Jan 21;137(3):420-428.

Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS., Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome, JCO Precis Oncol. 2021 Jan 5;5:PO.20.00355.

Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W.  A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Transplant, 2020 Nov;26(11):2139-2146.

Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid EG, O’Connor OA, Feingold J, Ardeshna KM, Townsend WM, Solh M, Heffner LT, Ungar D, Wang L, Boni JP, Havenith K, Qin YG, Kahl B.  Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, Blood. 2020 Nov 19.2020007512.

Solh MM, Baron J, Zhang X, Bashey A, Morris LE, Holland HK, Solomon SR., Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors. Biol Blood Marrow Transplant, 2020 Nov;26(11):2082-2088.

Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, Solh MM, Bashey A., Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv., 2020 Oct 27;4(20):5311-532.

Scott R Solomon 1 Andrew St Martin 2 Mei-Jie Zhang 3 Karen Ballen 4 Asad Bashey 1 Minoo Battiwalla 5 Lee Ann Baxter-Lowe 6 Claudio Brunstein 7 Saurabh Chhabra 8 Miguel Angel Diaz Perez, 9 Ephraim J Fuchs 10 Siddhartha Ganguly 11 Nancy Hardy 12 Peiman Hematti 13 Joseph McGuirk, 11 Edward Peres 14 Olle Ringden 15 David Rizzieri 16 Rizwan Romee 17 Melhem Solh 1 David Szwajcer, 18 Marjolein van der Poel 19 Edmund Waller 20 Basem M William 21 Mary Eapen 22 Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant, Biology of Blood and Marrow Transplant, 2020 Oct;26(10):1930-1936.

Ephraim Fuchs, M.D., Paul O’Donnell, M.D., Ph.D., Claudio Brunstein, M.D. Morris LE, Results of Blood and Marrow Transplant Clinical Trials Network Protocol 1101 a Multicenter Phase III Randomized Trial of Transplantation of Double Umbilical Cord Blood Vs. HLA-Haploidentical Related Bone Marrow for Hematologic Malignancy. Biol Blood and Marrow Trans, 2020 in press.

Solh MM, Speckhart D, Solomon SR, Bashey A, Morris LE, Zhang X, Holland HK., The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. Blood Adv., 2020 Oct 13;4(19):4812-4821.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, 2020 Sep 19;396(10254):839-852.

Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O’Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant, 2020 Aug;26(8):1459-1468.

Solomon SR, Solh M, Zhang X, Brown S, Jackson KC, Holland HK, Morris LE, Bashey A. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant. Blood Adv., 2020 Aug 11;4(15):3669-3676.

Solh MM, Baron J, Zhang X, Bashey A, Morris LE, Holland HK, Solomon SR. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.  Biol Blood Marrow Transplant, 2020 Aug 1: S10838791(20)30467-5.

Sutcliffe EG, Stettner AR, Miller SA, Solomon SR, Marshall ML, Roberts ME, Susswein LR, Arvai KJ, Klein RT, Murphy PD, Hruska KS.  Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing. Cancer Genet., 2020 Aug; 246-247:12-17.

Solomon SR, Martin AS, Zhang MJ, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LA, Brunstein C, Chhabra S, Perez MAD, Fuchs EJ, Ganguly S, Hardy N, Hematti P, McGuirk J, Peres E, Ringden O, Rizzieri D, Romee R, Solh M, Szwajcer D, van der Poel M, Waller E, William BM, Eapen M., Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant, Biol Blood Marrow Transplant. 2020 Jul 7.

Solh MM, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine). A.Leuk Res., 2020 Jun;93:106318.

Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O’ Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis. Bone Marrow Transplant, 2020 Jun 8.

Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, Cutler C, Alyea EP, Bachireddy P, Wu CJ, Ritz J, Streicher H, Ball ED, Bashey A, Soiffer RJ, Armand P. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, 2020 Jun 11;135(24):2182

Roboz GJ, Larson ML, Rubenstein SE, Solomon SR, Schiller GJ, An Q, Chiarella M, Louie AC,    Lin TL., Final safety and efficacy results from the CPX351 early access program for older patients with highrisk or secondary acute myeloid leukemia, Leuk Lymphoma, 2020 May;61 (5) :1188-1194.

—–Back To Top—–

Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv., 2020 May 12

Farhadfar N, Hsu JW, Logan BR, Sees JA, Chitphakdithai P, Sugrue MW, Abdel-Azim H, Anderlini PN, Bredeson C, Chhabra S, Diaz MA, Ganguly S, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Lynch DK, Murthy HS, Olsson RF, Papari M, Przepiorka D, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Yared JA, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR., Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield, Blood Adv., 2020 Feb 25;4(4):706-716.

Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M., Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR, J Clin Oncol., 2020 Feb 7:JCO1902408.

Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O’Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M.,Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT, Haematologica, 2020 Jan;105(1):47-58.

Solomon SR, Solh M, Jackson KC, Zhang X, K. Holland H, Bashey A, Morris LE., Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program, Bone Marrow Transplant, 2020 Jan;55(1):189-198.

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME., Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease, J Clin Oncol, 2019 Dec 20:JCO1903011.

Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A., Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy, Biol Blood Marrow Transplant, 2019 Nov;25(11):2211-2216.

Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M., Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy, Blood Adv., 2019 Oct 8;3(19):2836-2844.

LaPorte J, Leone K, Zhang X, Holland K, Morris L, Bashey A, Solh M, Solomon S., A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy, Journal of Oncology Pharmacy Practice, 2019 Sep;25(6):1336-1342.

Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ, Chu H, Rashidi A., HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis, Blood Adv., 2019 Sep 10;3(17):2581-2585.

Scott R. Solomon, Melhem Solh M, Katelin Jackson, Xu-Zhang, H. Kent Holland, Asad Bashey, Lawrence Morris, Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program, Bone Marrow Transplant: accepted August 25, 2019

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U,

Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019 Aug 15;25(16):5143-5155.

Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Brown S, Holland H, Morris L, Solh M, Bashey A, Safety and efficacy of rituximab-based first line treatment of chronic GVHD, Bone Marrow Transplant, 2019 Aug;54(8):1218-1226.

Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A. Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy, Biology of Blood Marrow Transplant, 2019 Jun 25, S1083-8791(19)30381-7 10.1016.

Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W., Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission, Blood Advances, 2019 Jun 25;3(12):1826-1836.

Karam E, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A, Solh M, Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?, Biology Blood Marrow Transplant, 2019 Jun 4. S1083-8791(19)30356-8.

Perales MA, Tomlinson B, Zhang MJ, St Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, Solh M, Wagner JE, Weisdorf DJ, de Lima M, Eapen M. Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical Donor?, Haematologica., 2019 May 17.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ., GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia, Blood Advances, 2019 May 14;3(9):1441-1449.

Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, S. Impact of T Cell Dose on Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Handgretinger R, Roy DC, O’Donnell P, Bashey A, Lazarus HM, Ballen K, Savani BN, Mohty M, Nagler A., Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation, Bone Marrow Transplant, 2019 May;54(5):784.

—–Back To Top—–

Gopalakrishnan S, D’Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma, Biology of Blood Marrow Transplant, 2019 Apr;25(4):683-688.

Solh M, Dickhaus E, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A., Fevers post infusion of T-cell replete HLA mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes, Bone Marrow Transplant, 2019 Apr 5.

Solh M, Solomon S, Morris L, Zhang X, Holland H, Bashey A, The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation, Biology of Blood Marrow Transplant, 2019 Mar;25(3):606-612.

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203), Lancet Hematology, 2019 Mar;6(3):e132-e143.

Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O’Donnell PV, Bashey A, Solomon S, Romee R, Gayoso J, Lazarus HM, Ballen K, Savani BN, Mohty M, Nagler A., The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation, Bone Marrow Transplant, 2019 Mar 4.

Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V, The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia, Blood Advances, 2019 Feb 26;3(4):670-680.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A, Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial, Journal of Clinical Oncology, 2019 Mar 1;37(7):589-597. Mchayleh W, Bedi P, Sehgal R, Solh M. Chimeric Antigen Receptor T-Cells: The Future is Now, Journal of Clinical Medicine, 2019 Feb 7;8 (2).

Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, T Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, A Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, M Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, M Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, A Ahmed I, Schouten HC, L Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR., Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation, Biology Blood Marrow Transplant, 2019 Feb;25(2):362-368.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh M, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK, Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation, Biology of Blood Marrow Transplant, 2019 Jan;25(1):73-85.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D’Souza A., Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups, Biology of Blood Marrow Transplant, 2018 Dec;24(12):2443-2449.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W., Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia, Blood Advances, 2018 Nov 13;2(21):2922-2936.

Spellecy R, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten I, Horwitz M, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris L, Horowitz MM, Majhail NS, Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biology of Blood Marrow Transplant, 2018 Oct;24(10):2145-2151.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE., Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML), Leukemia Research, 2018 Sep;72:92-95.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC., CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018 Sep 10;36(26):2684-2692.

Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Bashey A, Solomon S,  Solh M.  Comparison of outcomes following transplantation with T-replete HLA-haploidentical donor using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant, 2018. June; 53 (6):756-763.

Solomon S, Zhang X, Holland HK, Morris LE, Solh M, Bashey A. Superior survival of black versus white patients following post-transplant cyclophosphamide-based haploidentical= transplantation for adults with hematologic malignancy.  Biology of Blood & Marrow Transplantation, 2018. June;24(6):1237-1242.

Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M, Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure, Cancer, 2018 Jun 15;124(12):2541-2551.

Robinson TM, Fuchs EJ, Zhang MJ, St Martin A, Labopin M, Keesler DA, Blaise D, Bashey A, Bourhis JH, Ciceri F, Ciurea SO, Devine SM, Mohty M, McCurdy SR, Milpied N, McNiece IK, Rocha V, Romee R, Socie G, Yakoub-Agha I, Soiffer RJ, Eapen M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant and the Center for International Blood and Marrow Transplant Research, Related donor transplants: has post transplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?, Blood Advances, 2018 Jun 12;2(11):1180-1186.

Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma Leukemia, 2018 May;18(5):346-352.e5.

Ciurea S, Cao K, Fernadez-Vina M, Kongtim P, Malki M, Fuchs E, Luznik L, Huang X, Ciceri F, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D,             Handgretinger R, Roy D, O’Donnell P, Bashey A, Lazarus H, Ballen K, Savani B, Mohty M, Nagler A.  The European Society for Blood and Marrow Transplantation (EBMT)consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant, 2018  May;53(5):521-534.

Solh M, Bashey A, Solomon S, Morris LE, Zhang X, Brown S, Holland HK.  Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation:  a single center analysis of 389 consecutive patients.  Bone Marrow  Transplant,. 2018. May; 53(5):576-586.

Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW., Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants, Blood Advances, 2018 May 8;2(9):1022-1031.

Solomon S, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, Jackson K, Morris LE,  Holland HK, Solh M. Bashey A. Selecting the best donors for haploidentical transplant:  Impact of HLA killer cell immunoglobulin-like receptors genotyping, and other clinical variables. Biology of Blood & Marrow Transplantation, 2018. Apr;24(4):789-798.

Spellecy R, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten I, Horwitz M, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris L, Horowitz MM, Majhail NS, Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biology of Blood and Marrow Transplant, 2018 Apr 18. McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M., Effect of donor characteristics on haploidentical transplantation with post transplantation       cyclophosphamide, Blood Advances, 2018 Feb 13;2(3):299-307.

Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O’Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant, 2018 Jan 30.

Solh M. Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A, Solomon SR. Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation:  A single center analysis of 613 adult hematopoietic cell transplantation recipients using a modified endpoint. Biology of Blood & Marrow Transplantation, 2017. Dec;23(12):2192-2198.

Bashey A, Zhang M, Mccurdy S St. Martin A, Argall T, Ciurea S, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki M, Nakamura R, O’Donnell P, Pereles M, Raj K, Romee R, Rowley S, Rocha V, Salit R, Solh M, Soiffer R, Fuchs E, Eapen M.  Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell replete haploidentical donor using post- transplant cyclophosphamide. Journal of Clinical Oncology, 2017 Sep10;35(26):3002-9.

Holstein S, Jung S, Richardson P, Hofmeister C, Hurd D. Hassoun H, Giralt S, Stadtmauer E, Weisdorf D, Vij R. Moreb J. Callander N, Van Besein K, Gentile T, Isola L, Maziarz R. Bashey A.  Landau H, Martin T, Qazilbash M, Rodriguez C, McClune B, Schlossman R, Smith S, Hars V, Owzar K, Boyd M, Schultz C, Wilson M, Hari P, Pasquini M, Horowitz M, Shea T, Devine S, Linker C, Anderson K, McCarthy P.  Lancet Haematol, Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem cell transplantation for multiple myeloma: a randomized, double blind phase 3 trial. 2017. Sept;4 (9).

Webster J, Tibes R, Morris LE, et.al. Randomized Phase II Trial of Cytosine Arabinoside With and Without the CHK1 Inhibitor MK-8776 in Relapse and Refractory Acute Myeloid Leukemia, Leukemia Research. 2017, Sept. In Press.

Solh M. Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A, Solomon SR. Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation:  A single center analysis of 613 adult hematopoietic cell transplantation recipients using a modified endpoint. Biology of Blood & Marrow Transplantation, 2017. Aug 30.

Solomon S, Sizemore C, Zhang X, Ridgeway M, Solh M, Morris LE, Holland HK, Bashey A.  Current Graft-versus host disease free.  Relapse-free survival:  A dynamic endpoint to better define efficacy after allogenic transplant. Biology of Blood & Marrow Transplantation. 2017, Jul;23(7):1208-1214.

Hamilton B, Rybicki L, Abounader D, Adekola K, Aldoss I, Bachanova V, Bashey A, Brown S, DeLima M, Devine S, Flowers C, Ganguly S, Jagasia M, Kennedy V, Kim D, McGuirk J, Pullarkat V, Romee R, Sandhu K, Smith M, Ueda M, Viswabandya A, Vu K, Wall S, Zeichner S, Perales M, Majhail N, Advani A.  Allogeneic hematopoietic cell Transplantation for adult T cell acute lymphoblastic leukemia. Biology of Blood & Marrow Transplantation, 2017. Jul;23(7):1117-1121.

Haverkos B, Abbott D, Hamandani M, Armand P, Flowers M, Merryman R, Kamdar M      Kanate A, Saad A, Mehta A, Ganguly S, Fenske T, Hari P, Lowsky R, Andritsos L,       Jagasia M, Bashey A, Brown S, Bashanova V, Stephens d, Mineishi S, Nakamura R, Chen Y, Blazar B, Gutman J, Devine S. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high rate but frequent GVHD,   Blood, 2017. July13;130(2):221-228.

Gerds A, Woo a, Hu Z, Abdel Azim H, Akpek G Aljurf M, Ballen K, Beitinjaneh A, Bacher U, Cahn J, Chhabra S, Cutler C, Daly A, Deflipp Z, Gale R, Gergis U Grunwald M, Hale G, Hamilton B, Jagasia M, Kamble R, Kindwall-Keller T, Nishihori T, Olsson R, Ramanathan M, Saad A, Solh M. Ustun C, Valcarcel D, Warlick E, Wirk B, Kalaycio M, Alyea E, Popat U, Sobecks R, Saberr W., Outcomes after umbilical cord blood transplantation for myelodysplastic  syndrome. Biology of Blood & Marrow Transplantation, 2017 June;23(6):971-79.

Khoury H, Wang T, Hemmer M, Couriel D, Alousi A, Cutler C, Aljurf M, Antin  J, Ayas M, Battiwalla M, Cahn J, Cairo M, Chen Y, Gale R, Hashmi S, Hayashi R, Jagasia M, Juckett M, Kamble R, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoeman H, Schouten H, Socie G, Storek J, Verdonck L, Vij R, Wood WA Yu L, Martino R, Carabasi M, Dandoy C, Gergis U. Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz K, Wirk B, Spellman S, Arora M, Pidala J.  Improved survival after acute graft-versus-host disease diagnosis in modern era, Haematologica, 2017 May;102(5): 958-66.

Brunstein C, Zhang M, Baker J, St. Martin A, Bashey A, DeLima M, Dehn J, Hematti P, Perales M, Rocha V, Territo M, Weisdorf D, Eapen M., The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia, Haematologica,  2017. May;102(5):941-947.

Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D, Maziarz R, Warlick E, Fernandez H, Alyea E, Hamadani M, Bashey A, Giralt S, Geller N, Leifer E, Le-Rademacher J, Mendizabal A, Horowitz M, Deeg H, Horwitz M.  Myeloablative versus reduced intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. Journal of Clinical Oncology, 2017, Apr10;35(11): 1154-1161.

—–Back To Top—–

Cornell R, D’Souza A, Kassim A, Costa L, Innis-Shelton R, Zhang M, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz M, Freytes C, Gale R, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble R, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Lazarus H, Lee C, aiolino A, Marks D, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson R, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk B, Yared J, Krishnan A, Mark T, Nieto Y, Hari P.  Maintenance versus induction therapy choice on outcomes after autologous transplantation for multiple myeloma, Biology of Blood & Marrow Transplantation, 2016, 11. 011 Nov 14.

Srour S, Milton D, Bashey A, Karduss-Urueta A, Malki M, Romee R, Solomon S, Brown S, Slade M, Perez R, Rondon G, Forman S, Champlin R, Kabriaei P, Ciurea S. Haploidentical transplantation with post-transplantation cyclophosphamide for high risk acute lymphoblastic leukemia. Biology of Blood & Marrow Transplantation, 2016, Oct; 22(10): 1861-1866.

Solomon SR, Sizemore C, Zhang  X, Brown S, Holland HK, Morris LE, Solh M, Bashey A, Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation for acute Leukemia. Biology of Blood and Marrow Transplantation, October, 2016, Vol. 22, Issue 10, pages 1816–1822.

Solh M, Solomon S, Morris L, Holland HK, Bashey A.  Extramedullary Acute Myelogenous Leukemia.  Blood, Sept; 30(5):333-9.

Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE, Thompson J, Horowitz MH, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder RF.  Autologous hematopoietic cell transplantation for HIV-related lymphoma:  Results of the BMT CTN 0803 (AMC) 071 Trial.  Blood, 2016. Aug 25; 128(8):1050-8.

Gorgeis J, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A, Solh M.  T-Cell replete HLA—haploidentical donor transplantation (HIDT) with post-transplant cyclophosphamide (PTCY) is an effective salvage for patients relapsing after an HLA-matched related (MRDT) or a matched unrelated donor transplantation (MUDT). Biology of Blood & Marrow Transplantation, 2016 Oct;22(10): 1861-6

Solomon SR.  Haploidentical versus matched unrelated donor PBSC transplant AML:  Should donor type matter anymore?  Biology of Blood & Marrow Transplantation, 2016 Sept; 22(9):1540-2.

Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A.   Factors predicting graft-versus-host disease-free. Relapse-free survival after allogeneic  hematopoietic cell transplantation:  Multivariable analysis from a single center. Biology of Blood & Marrow Transplantation, 2016, Aug;22(8):1403-1409.

Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A. Post-relapse survival after haploidentical transplantation vs matched-related or matched unrelated hematopoietic cell transplantation. Bone Marrow Transplantation, 2016 Jul;51(7):949-54.

Davids M. Kim H, Bachireddy P, Costello C, Liguori R, Savell A, Lukez A, Avigan D, Chen Y, McSweeney P, LeBoeuf N, Rooney M, Bowden M, Zhou C, Granter S, Hornick J, Rodig            S, Hirakawa M, Severgnini M, Hodi F, Wu C, Ho V, Cutler C, Koreth J, Alyea E, Antin J, Armand P, Streicher H, Ball E, Ritz J, Bashey A, Soiffer R. Ipilimumab for patients with relapse after allogeneic transplantation. Leukemia and Lymphoma Society Blood Cancer Research Partnership, New England Journal of Medicine. 2016, July 14;375(2): 143-53.

Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, Lee DA, Altomare DA, Copik AJ.   NK cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment, Cryotherapy, 2016 May;18(5):653-63.

Solh M, Shanley R, Mc Cullough J, Weisdorf D. Blood transfusions and pulmonary complications following hematopoietic cell transplantation, Transfusion, 2016 Mar;56(3):653-61.

Solomon, SR, Haploidentical versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia: Should Donor Type Matter Anymore? Biology of Blood and Transplantation, Volume 22, Issue 1, January 2016, Pages 125-133.

Solomon SR, Solh M, Morris LE, Holland HK, Bashey A.  Myeloablative conditioning with PBSC grafts for T Cell-Replete haploidentical donor transplantation using post-transplant   cyclophosphamide.  Hindawi Publishing Corporation:  Advances in Hematology, Vol. 2016 Article ID 9736564 7 pages.       

Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M,  Solh M, Morris LE, Holland HK, Solomon SR, Comparison of Outcomes of Hematopoietic Cell Transplant from T-Replete Haploidentical Donors Using Post Transplant Cyclophosphamide with 10 of 10 HLA-A, -B,-C, -DRB1, and –DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis including Disease Risk Index, Biology of Blood and Transplantation, Volume 22, Issue 1, January 2016, Pages 125-133.

LaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed hodgkin’s lymphoma, Journal of Clinical Practice, 2015 Dec 11.

Klyuchnikov E, Bacher U, Kroger NM, Hari Pn, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D’Souza A, Freytes CO, Gale RP, Ganguly S Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Millier AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R,

Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M.  Reduced-intensity allografting as first transplantation approach in relapse/refractory grade one and two follicular lymphoma provides improved outcomes in long-term survivors.  Biology Of Blood and Marrow Transplantation, 2015 Dec; 21 (12): 2091-2099.

Inamoto Y, Flowers ME, Wang T, Solh M, et al. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia, Biology Of Blood and Marrow Transplantation, 2015 Oct; 21(10):1776-82.

Seftel M, Neuberg D, Zhang M, Wang H, Akpek G, Bachanova V,  Bacher U, Ballen K, Baron F, Bashey A, Bergeron J, Cahn J, Camitta B, Copelan E, Couban S, DeAngelo D, Lima M, Deol A, Freytes C, Gale R, Gergis U, Hamadani M, Hogan W, Kebriaei P Kharfan-abaja M, Lazarus H, Litzow M, Loren A, Miller A,

Nishihori T, Norkin M, Olsson RR., Reshef R, Saber W, Sabloff M, Sandmaier B, Sallan S, Savani B, Schouten H, Tallman M, Vij R, Woolfrey A, Wiernik P, Wirk B, Wood W, Weisdorf D. Superior outcomes of Pediatric-inspired intensive chemotherapy over allogeneic hematopoietic cell Transplantation for Philadelphia chromosome negative adult all in first complete Remission:  A combined analysis of Dana-Farber All Consortium and CIBMTR Cohorts, The Lancet Oncology, 2015.

Solomon SR, Sizemore CA, Ridgeway M, Zhang X, Smith J, Brown S, Holland HK, Morris LE, Bashey A.  Costicosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab, Biology of Blood & Marrow Transplantation, 2015 Sept;21(9): 1576-1582.

Zeidner J, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.  Radomized multi-center phase II study of  flavopiridol (alvocidib), cytarabine, and mitoxantrone (flam) versus cytarabine/ daunorubicin (7+3) in newly diagnosed acute myeloid leukemia, Haematologica, 2015 Sept; 100(9):1172-9.

—–Back To Top—–

Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS,Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O’Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringden OT, Rocha V, Vij R, Weisdorf  DJ, Champlin RE, Horowitz MM, Fuch EJ, Eapen M. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia, Blood,  2015 Aug 20; 126(8): 1033-1040.

Solomon SR, Sizemore C, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A.  Total Body Irradiation-based myeloablative haploididentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors,  Biology of Blood & Marrow Transplantation,  2015 July;21(7):1299-1307.

Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: pathogenesis, diagnosis and current and emerging treatment options. J Blood Med, 2015 July 8; 6:219-27

Holland KH.  New Targeted Treatments for Hematological Malignancies. Atlanta Medicine: Journal of the Medical Association of Atlanta, 2015, July Vol.86, No. 2:12-17.

Sanacore M, Zhang X, Brown S, Connor K, Hilton S, Morris LE, Holland HK, Solomon SR, Bashey A.     Preferential depletion of host over donor T-cells through in vivo decay of active rabitt-anti-thymocyte globulin levels during reduced intensity conditioning, Bone Marrow Transplantation, 2015 Jun;50(6): 829-833.

LaPorte J, Morris LE, Koepke J.  Long complete remission achieved with the combination therapy of cisplatin and gemcitabine in patients with aggressive natural killer cell leukemia. Case Reports in Hematology, Volume 2015, Article ID 715615.

Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-life experience of a brief arsenic toxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: Favorable outcomes with limited anthracycline exposure and shorter consolidation therapy, Clinical Lymphoma, Myeloma, Leukemia, 2015 May;15(5): 292-297.

Oyer JL, Igarashi R, Solh M, Copik AJ. Generation of highly cytotoxic natural killer cells for treatment of AML using a feeder free, particle-based approach, BBMT, 2015 April; 21(4):632-9.

Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B.  Phase III open-lable randomized study of cytarabine incombination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia, Journal of Clinical Oncology 2015 Apr 10;33(11): 1252-1257.

Batista A, Lamontagne D, Solh M. Processing the 5-ml umbilical cord blood unit with the use of an automated wash procedure, Cytotherapy 2015 Mar;17(3):336-7.

Arai S, Arora M, Solh M, Pavletic SZ. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research, BBMT, 2015 Feb;21(2):266-74.

Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE.  Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation, Biology of Blood and Marrow Transplantation, 2014; Dec;20(12): 1949-57.

Bashey A, Solomon SR.  T-Cell replete haploidentical donor transplantation using post transplant CY”:  An emerging standard of care option for patients who lack and HLA-identical sibling donor, Bone Marrow Transplantation, 2014, Aug;49(8): 999-1008.

Bashey, A, Solomon, S. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor, Bone Marrow Transplantation, advance online publication, 19 May 2014; doi:10.1038/bmt.2014.62.

Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O’Connell C, Solomon, SR, Pigneax A, Vey N, Hills R, Jacobsen TF, Gianella Boradori A, Foss O, Vetrhusand S, Giles FJ.  International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed refractory acute myeloid leukemia, Journal of Clinical Oncology, 2014; 32(18):1919-1926.

Sabloff M, Sobecks RM, Ahn KW, Zhu X, De Lima M, Brown JR, Inamato Y, Holland HK, Aijurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortis J, Maziarz RT, Gale RP, Saber W.,Does total body irradiation conditioning improve outcoes of myeloablative human leukocyte antigen identical sibling transplantations for chronic phocytic leukemia,  Biology of Blood & Marrow Transplantation, 2014 Mar; 20(3) 421-424.

Solomon SR, SanacoreM, Zhang X, Brown, S, Holland K, Morris, LE, Bashey A. Calcineurin Inhibitor (DNI)-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide (CY) and Brief-Course Sirolimus Following Reduced Intensity Peripheral Blood Stem Cell Transplantation, Biology of Blood and Marrow Transplantation (2014), doi: 10,1016/j.bbmt.2014.07.020.

Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ.  Phase 2 trial of CPX 351, a fixed 5:1 molar ratio of cytarabine/daunorubicin vs cytarabine/daunorubicin in older adults with untreated AML, Blood, 2014;123(21):3239-3246.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobaldi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA,Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J,Lonial S, Krishnan A, Dispenzieri A, Hari P.  Salvage second hematopoietic cell transplantation cell transplantation in myeloma.  Plazma Cell Disorders Working Committee of The Blood and Marrow Transplant,  Biology of Blood & Marrow Transplantation, 2013 May; 19(5): 760-6.

Bashey A., Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, Morris LE, and Solomon SR.  T-Cell Replete HLA-Haploidentical Hematopoietic Transplants For Hematologic Malignancies Using Post-Transplant Cyclophosphamide Result In Equivalent Outcomes To Contemporaneous Transplants From HLA-Identical and Matched Unrelated Donors. Journal of Clinical Oncology 2013; Apr;31(10):310-1316.

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A.  Haploididentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival:  Results of a Prospective Phase II Trial, Biology of Blood & Marrow Transplantation, 2012 December; 18(12):  1859-1866.

Philip L. McCarthy, M.D., Kouros Owzar, Ph.D., Craig C. Hofmeister, M.D., David D. Hurd, M.D., Hani Hassoun, M.D., Paul G. Richardson, M.D., Sergio Giralt, M.D., Edward A. Stadtmauer, M.D., Daniel J.

Weisdorf, M.D., Ravi Vij, M.D., Jan S. Moreb, M.D., Natalie Scott Callander, M.D., Koen Van Besien, M.D., Teresa Gentile, M.D., Ph.D., Luis Isola, M.D., Richard T. Maziarz, M.D., Don A. Gabriel, M.D., Ph.D., Asad  Bashey, M.D., Ph.D., Heather Landau, M.D., Thomas Martin, M.D., Muzaffar H. Qazilbash, M.D., Denise Levitan, M.D., Brian McClune, M.D., Robert Schlossman, M.D., Vera Hars, M.S., John Postiglione, B.A., Chen Jiang, Ph.D., Elizabeth Bennett, B.H.E., Susan Barry, B.A., Linda Bressler, Pharm.D., Michael Kelly, M.A., Michele Seiler, M.S., Cara Rosenbaum, M.D., Parameswaran Hari, M.D., Marcelo C. Pasquini, M.D., Mary M. Horowitz, M.D., Thomas C. Shea, M.D., Steven M. Devine, M.D., Kenneth C. Anderson, M.D., and Charles Linker, M.D., Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma New England Journal of  Medicine, 2012; 366:1770-1781 May 10, 2012.

Vogl D, Wang T, Perez W, Stadtmauer E, Heitjan D, Lazarus H, Kyle, RA, Kamble R, Weisdorf D, Roy V, Ballen K, Holmberg L, Bashey A, McCarthy P, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P.  Effect of obesity on outcomes after autologous hematopoietic  stem cell transplantation for multiple myeloma,  Biology of Blood & Marrow Transplantation, 2011 Dec;17(12): 1765-74.

Judith E. Karp, Tatiana I.Vener, Mitch Raponi, Ellen K. Ritchie, B.Douglas Smith, Steven D. Gore, Lawrence E. Morris, Eric J. Feldman, acqueline M.Greer, Sami Malek, Hetty E. Carraway, Valerie Ironside, Steven Galkin, Mark J.Levis, Michael A. McDevitt, Gail R. Roboz, Christopher D. Gocke, Carlo Derecho, John Palma, Yixin Wang, Scott H. Kaufman, John J. Wright and Elizabeth Garrett-MayerMulti-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia, Blood, 2011 October 14.

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C.  Reduced – Intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation:  A multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002), Biology of Blood & Marrow Transplantation, 2011 Apr;17(4) 558-65.

Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, Isola L, Baxter-Lowe LA, Kelly M, Owzar K, Linker C; For the Cancer leukemia Group B.  Reduced-intensity Allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies:  CALGB 109901, Biology of Blood & Marrow Transplantation, 2011 Feb 3.

Chu R, Bazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, Marsh J, Russell J, Sabloff M, Waller EK, Eapen M.  Comparison of outcomes after transplantation of G-CSF – stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia, Biology of Blood & Marrow Transplantation, 2010 October 27.

—–Back To Top—–

Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Soiffer R, Mitrovich RC, Lowy I, Ball ED.  CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not increased levels of T regulatory cells,  Biology of Blood & Marrow Transplantation, 2010 Aug 13.

Kasamon Y, Luznik L, Leffell M, Kowalski J, Tsai H, Bolanos-Meade J, Morris LE, Crilley P, O’donnell P, Rossiter N, Huff C, Brodsky R.  Nonmyeloablative HLA-haploidentical BMT with high dose post transplantation cyclophosphamide:  analysis of outcomes in relation to HLA disparity,  Biology of Blood and Marrow Transplantation, 2010 April;16(4): 482-9. 

Solomon SR, Matthews RH, Barreras AM, Bashey A, Manion KL, McNatt K, Speckhart D. Connaghan DG, Morris LE, Holland HK.  Outpatient myeloablative allo-SCT:  a comprehensive approach yields decrease hospital utilization and low TRM, Bone Marrow Transplantation, 2010 March;45(3): 468-75.

Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B, Cervantes F, Devine S, Gale R, Gupta V, Hahn T, Hogan W, Kroger N, Litzow M, Marks D, Maziarz R, McCarthy P, Schiller G, Schouten H, Wiernik P, Horowitz M, Giralt S, Arora M.  Outcome of Transplantation for Myelofibrosis, Biology of Blood & Marrow Transplantation, 2010 March; 16(3): 358-67.

Hari P, Majhail N, Zhang M, Hassebroek A, Siddiqui F, Ballen K. Bashey A, Bird J, Freytes  C, Gibson J, Hale G, Holmberg L, Kamble R, Kyle R, Lazarus P, LeMaistre C, Loberiza F, Maiolino A, McCarthy P, Milone G, Omondi N, Reece D, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee S, Rizzo J, Mehta P.  Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma,  Biology of Blood & Marrow Transplantation, 2010 March;16(3): 395-402.

Gore S, Gojo I, Sekeres M, Morris LE, et al.  A Single Cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia, Journal of Clinical Oncology, 2010 Feb 20; 28(6): 1047-53.

Schiller GL, O’Brien SM, Pigneux A, DeAngelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ.  Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia,  J Clin Onc, 2010; 28(5):815-821.

Reese DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN.  Outcome of patients with IgD and IgM Multiple Myeloma undergoing Autologous hematopoietic stem cell transplantation:  A retrospective CIBMTR Study, Clinical Lymphoma Myeloma Leukemia, 2010 Dec1;10(6): 458-63.

Jung A, Holman P, Castro J, Carrier E, Bashey A, Lane T, Nelson C, Pu M, Messer K, Corringham S, Ball E.  Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia, Biology of Blood & Marrow Transplantation,  2009 Oct;15(10): 1306-13.

Hari P, Zhang M, Roy V, Perez W, Bashey A, To LB, Elfenbein G, Freytes C, Gale R, Gibson J, Kyle R, Lazarus H, McCarthy P, Milone G, Pavlovsky S, Reece D, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D.  Is the international staging system superior to the Durie-Salmon staging system?  A comparison in multiple myeloma patients undergoing autologous transplant, Leukemia, 2009 August;23(8): 1528-34.

Karp J, Flatten K, Feldman E, Greer J, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith DB, IronsideV, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore S, Levis MJ, Wright JJ, Garrett- Mayer E, Kaufmann S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous   leukemia: A preclinical and phase I trial of the farnesyltransferase inhibitor tripifarnib (R115777, Zarnestra) combined with etoposide, Blood, 2009 May 14;113(20): 4841-52.

Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED.  CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation, Blood, 2009 Feb 12; 113(7): 1581-8.

Kumar S, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy  PL, Milone GA, Moreb JS, Pavlovsky S, Reese DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation, Biology of Blood & Marrow Transplantation, 2008 Oct;14;(10): 1134-40.

Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. Comparison of Twin and autologous transplants for multiple myeloma,  Biology of Blood & Marrow Transplantation, 2008 Oct; 14(10): 1118-24.

Smith SM, Van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Paviovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P., Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant, Biology of Blood & Marrow Transplantation, 2008 Aug;14(8):904-12.

Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris LE, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor risk features, Clinical Cancer Research, 2008 May; 14(10): 3077-82.

Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic. Hematopoietic cell transplantation for metastatic breast cancer, Bone Marrow Transplant, 2008, Mar;41(6): 537-45.

Raponi M, Lancet J, Hongtao F, Dossey L, Lee G, Gojo I, Feldman E, Gotlib J, Morris LE, Greenberg P, Wright J, Harousseau J, Lowenberg B, Stone R, De Porre P, Wang Y, Karp J.  A two-gene classifier for predicting response  to the farnesyltransferase Ihibitor tipifarnib in acute myeloid leukemia, Blood, 2008 Mar 1; 111(5): 2589-96.

Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Buchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Dohner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A; CIBMTR Acute Leukemia Working Committee.  HLA-Identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission:  Collaborative study between the German AML Intergroup and CIBMTR, Biology of Blood & Marrow Transplantation,  2008 Feb; 14(2):187-96.

Karp JE, Giles FJ, Gojo I, Morris LE, Greer J, Johnson B, Thein M, Low J.A phase 1 study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractoryacute leukemias and aggressive myeloproliferative disorders, Leukemia Research, January 2008; 32(1): 71-7.

Bashey A, Donohue M, Lin L, Medina B, Corringham S, Ihasz A, Carrier E, Castro J, Holman P, Ronghui X, Law P, Ball E, Lane T.  Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-simulating factor and granulocyte- colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation, Transfusion, 2007 Nov; 47(11): 2153-60.

Mielke S, Rezvani K, Savani B, et al.  Reconstitution of foxp3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease (GvHD), Blood, 2007 Sep; 110:1689-97.

Baek W, Bashey A, Sheean G.  Complete remission induced by rituximab in refractory, seronegative, muscle specific, kinase-positive myasthenia gravis,  J Neurol Neurosurg Psychiatry, 2007, July;78(7): 771.

Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE.  Home administration of high-dose oral busulfan in patients undergoing  hematopoietic stem cell transplantation,  Bone MarrowTransplantation, 2007 Apr;39(7): 397-400.

Lancet J, Gojo I, Gotlib J, Feldman E, Greer J, Liesveld J, Bruzek L, Morris L, et.al: A Phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly  patients with previously untreated acute myelogenous leukemia,  Blood, 2007 Feb15; 109(4):1387-1394.

Kebriaei P, Isola L, Bahceci E, Holland HK, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Uberti J.  306:  Successful phase II trial using Mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft-vs-host disease (aGVHD), Biology of Blood and Marrow Transplantation, 2007 Feb;3(2): 111.

Anagnostopoulos A, Hari P, Perez W, Ballen K, Bashey A, Bredeson C, Freytes C, Gale R, Gertz M, Gibson J, Goldschmidt H, Lasarus H, McCarthy P, Reece D, Vesole D, Giralt S.  Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia, Biology of Blood & Marrow  Transplantation, 2006, Aug;12(8):  845-54.

Melenhorst JJ, Solomon SR, Shenoy A, et al.  Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells,  J Immunotherapy, 2006 Jul-Aug;29(4):436-43.

Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, and Ball ED. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged sixty or older, Leukemia Res., 2006, April;30(4): 503-6.

Tallman M, Perez W, Lazarus H, Gale R, Maziarz R, Rowe J, Marks D, Cahn J, Bashey A, Bishop M, Christiansen N, Frankel S, Garcia J, Llhan O, Laughlin M, Liesveld J, Linker C, Litzow M, Luger S, McCarthy P, Milone G, Pavlovsky S, Phillips G, Russell J, Saez R, Schiller G, Sierra J, Weiner R, Zander A, Zhang M, Keating A, Weisdorf D, Horowitz M. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission,  Biology of Blood & Marrow Transplantation, 2006, Feb;12(2): 204-16. Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, Solomon SR, Barrett AJ., Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning, British Journal of Hematology, 2005 Sep;130(5):733-9.

Gore SD, Smith DB, Gojo I, Morris LE, et al:  Durable molecular remission with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia, American Journal of Hematology, 2005 June; 79(2): 119 -127.

Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ,McCarthy P, et. al.  Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients, Biology of Blood and Marrow Transplantation: 2005 May; 11(5): 389-98.

Solomon SR, Savani B, Montero A, et al., Improved Outcomes for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome, Biology of Blood Marrow Transplant 2005; 11:619-26.

Solomon SR, Mielke S, Savani BN, et al.  Selective depletion of alloreactive donor lymphocytes- a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation, Blood, 2005; 106(3):1123-9.

Mielke S, Solomon SR, and Barrett AJ.  Selective Depletion Strategies in Allogeneic Stem Cell Transplantation, Cytotherapy, 2005; 7(2):109-15.

Savani BN, Montero A, Wu C, Nlonda N, Read E, Dunbar C, Childs R, Solomon S, and Barrett AJ.  Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation, Biology of Blood Marrow Transplant 2005; 11:223-230.

Karp J, Gojo I, Pili R, Morris LE, et al.  Targeting vascular endothelial growth factor (VEGF) for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d- arabinofuranosylcytosine, mitoxantrone, and bevacizumab, Clinical Cancer Research, 2004 June1; 10(11): 3577-85.

Jacobsohn DA, Anders V, McMillan S, Morris LE, et al: Infliximab for the treatment of acute GVHD:  A review and case series, American Journal of Hematology, 2003 Oct; 74(2): 119-24.

Reece DE, Foon KA, Bhattarcharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL., Use of the anti- idiotype Breast Cancer Vaccine 11D10 in Conjuction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer, Clinical Breast Cancer, 2003 Feb;3 Suppl 4: S152-7.

Reece DE, Foon, KA, Battacharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG,  Dipersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A,  Phillips GL., Interim Analysis of the use of the Anti-Idiotype Breast Cancer Vaccine 11D10 (TriAb) in conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer, Clinical Breast Cancer, 2001 Apr;2(1): 52-8.

Owen P, Connaghan DG, Holland HK, Steis RG., Bone Marrow Transplantation: Cancer therapy comes of age, Journal of Medical Association of Georgia, 1998 Apr;87(2): 145-6, 148.

Bomberger C, Singh–Jairam M, Rodney G, Guerriero A,Yeager AM, Fleming WH, Holland HK, Waller EK.,  Lymphoid Reconstitution Following Autologous PBSC Transplantation with FACS sorted CD34+ Hematopoietic Progenitors, Blood, 1998 Apr1;91(7): 2588- 600.

—–Back To Top—–